$10.9M NCI Grant For Studies Of Virus Cancer Models
Main Category: Cancer / OncologyAlso Included In: Lymphoma / Leukemia / Myeloma; Infectious Diseases / Bacteria / Viruses; HIV / AIDS
Article Date: 19 Jul 2008 - 10:00 PDT
| Patient / Public: | ![]() |
4 (1 votes) |
| Healthcare Prof: | ![]() |
A team of researchers from Ohio State University's Comprehensive Cancer Center (OSUCCC) and the University's College of Veterinary Medicine have received a $10.9 million, five-year grant from the National Cancer Institute (NCI) to further their studies of retrovirus-associated cancer.
Principal investigator Michael Lairmore, DVM, PhD, professor and chair of the Department of Veterinary Biosciences, associate director for basic research at the OSUCCC, and a member of the OSUCCC's Viral Oncogenesis Program, leads the team.
The new grant follows a previous five-year, $8.9 million NCI grant received in 2003 for studies investigating how some retroviruses cause white blood cells, called lymphocytes, to proliferate, leading to cancer. Retroviruses include the human T-lymphotropic virus type I and II (HTLV-1 and HTLV-2), which have been linked to adult T-cell leukemia and lymphoma, and the human immunodeficiency virus (HIV), the cause of AIDS.
The study comprises five interactive projects with interrelated goals to define critical biological events that control the alteration of lymphocytes. "These findings will help us further discover therapeutic targets against retroviral-induced lymphoma and its lethal side effects syndromes, such as hypercalcemia," Lairmore says.
###
Source: Darrell E. Ward
Ohio State University Medical Center
Visit our cancer / oncology section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/115465.php>
APA
http://www.medicalnewstoday.com/releases/115465.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.





